Trial Information
A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
